Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

percent with TRA (43 percent reduction).

TRAP-induced platelet aggregation inhibition was also measured. In those receiving the three oral loadings doses, platelet inhibition of greater than or equal to 80 percent was seen in 42.9 percent, 52.9 percent and 96.3 percent of study patients at each respective dose 120 minutes post-TRA administration. In maintenance doses, inhibition greater than or equal to 80 percent was seen in 90.9 percent, 100 percent and 100 percent of patients at each respective dose at 30 and 60 days compared to 9.1 and 11.1 percent at 30 and 60 days for patients receiving standard of care.

About the Phase III Trials

TRA is currently being evaluated in two large-scale multinational, randomized, double-blind, placebo-controlled Phase III clinical trials.

The Phase III Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P-TIMI 50) trial is a multinational, randomized, double-blind, placebo-controlled study in approximately 19,500 patients with prior MI or stroke, as well as patients with existing peripheral arterial disease. Patients will be randomized to either placebo plus standard medical care (including aspirin and clopidogrel) or to TRA once daily plus standard medical care. This Phase III trial uses the 2.5 mg maintenance dose. The primary endpoint of the trial is the composite of cardiovascular death, MI, urgent coronary revascularization or stroke. The key secondary endpoint is the composite of cardiovascular death, MI or stroke. Patients will be followed for a minimum of one year. This Phase III trial is being conducted by the Thrombolysis in Myocardial Infarction (TIMI) Study Group.

The Phase III Thrombin Receptor Antagonist Clinical Event Reduction in acute coronary syndrome (TRA-CER) trial is a multinational, randomized, double-blind, placebo-controlled study in approximately 10,000 patients with non-ST-seg
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Tenn. , July 28, 2015 Cumberland ... it will release second quarter 2015 financial results after ... conference call and live Internet webcast will be held ... Time to discuss the results. To participate ... or 253-237-1032 (for international callers).  A rebroadcast of the ...
(Date:7/28/2015)... Mass., July 28, 2015  Psychemedics Corporation (NASDAQ: ... the period ended June 30, 2015.  The Company also ... to shareholders of record as of August 7, 2015 ... be the Company,s 76 th consecutive quarterly dividend. ... June 30, 2015 was $7.0 million versus $7.7 million ...
(Date:7/28/2015)... /PRNewswire-USNewswire/ -- Kentucky,s ... after a 2012 law required providers to check a ... yet more evidence that Californians need the same protections, ... Kentucky,s prescription drug abuse legislation took ... 52 percent; opioid prescriptions to doctor-shopping individuals dropped by ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8Study Shows Requiring Prescription Drug Database Use Before Prescribing Powerful, Addictive Medications Critical In Ending Growing Epidemic, says Consumer Watchdog 2
... to lower health spending, the independent drugstore lobby is pushing new ... Care Management Association (PCMA) has launched a new ad campaign ... Click here ... independent drugstores new powers to collectively bargain, evade routine, anti-fraud audits, ...
... May 24, 2011 For the fifth straight year, ... Society of Clinical Oncology (ASCO) Electronic Health Records (EHR) ... the spotlight will be Elekta,s MOSAIQ® Oncology Information System, ... Meaningful Use under the federal government,s HITECH Act. MOSAIQ ...
Cached Medicine Technology:It's No Joke: Independent Drugstores Want Congress to Help Them Raise Prescription Drug Costs 2It's No Joke: Independent Drugstores Want Congress to Help Them Raise Prescription Drug Costs 3Elekta to Feature Certified MOSAIQ EHR at Electronic Health Records Lab During the 2011 ASCO Annual Meeting 2
(Date:7/28/2015)... ... ... Rosa’s The Press Democrat announced its annual report of the very best facilities in Sonoma ... took the top spot as the Best Cosmetic Surgeons in Sonoma County . ... bestowed such a prestigious title. , The Press Democrat was Santa Rosa’s first ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... patented products, announces Shelled Out, a new household invention that makes shelling eggs ... $253.4 billion by 2020,” says Scott Cooper, CEO and Creative Director of World ...
(Date:7/28/2015)... ... 28, 2015 , ... The Denver Foundation and Blair-Caldwell African ... Exhibited,” a photographic and narrative exploration of African American giving, which runs August ... , Denver is one of only ten cities to host “The Soul of ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... United States with 1 in 68 children currently affected with the disorder. For ... child on the road to recovery is extremely daunting. That’s where Talk About ...
(Date:7/28/2015)... ... July 16, 2015 (PRWEB) July 28, 2015 ... ... Miami, FL, that specializes in providing Health insurance quotes to its clients, recently ... compare auto insurance rates that best suits their specific needs. , Liability ...
Breaking Medicine News(10 mins):Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2
... ORLANDO, Fla. Results of a study presented at the ... credence to the idea that improving quality of life affects ... cancer. Researchers know that telomeres shorten and deteriorate with ... length. "We are trying to understand the interconnections between ...
... , FRIDAY, April 1 (HealthDay News) -- At-home pregnancy tests ... on the way and if it is time to call ... offer tantalizing clues about future health risks -- are still ... results may puzzle or even panic consumers who don,t seek ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... Germany, Saturday 02 April 2011: Exciting new data presented ... quadruple therapy in chronic hepatitis C (HCV) patients suppressed ... 100% rate of sustained virological response - undetectable HCV ... the quadruple therapy study, HCV patients were given four ...
... Fla. The combination of two compounds that inhibit ... showing promise in an ongoing Phase I trial, according ... 2011, held here April 2-6. The research, ... GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. ...
... (HealthDay News) -- Updated guidelines to keep children happy, safe ... week by the American Academy of Pediatrics. When deciding ... and overall well-being, to ensure their child can effectively participate ... and mentally prepare their child for camp, and team with ...
Cached Medicine News:Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 3Health News:Antidepressants linked to thicker arteries 2Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2
... multi-drug test device provides clear, ... Negative results can be determined ... minutes; positive results require only ... urine sample application will dependably ...
... The QuickScreen™ At Home Drug Test is the ... FDA for home use. The kit includes a ... to read instructions, a handbook with frequently asked ... the sample to the laboratory if the screening ...
... is a quantitative microplate enzyme immunoassay that can ... for rapid recurrence or occult disease. The test ... and is twice as sensitive as urine cytology. ... outcome by identifying those patients who may benefit ...
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
Medicine Products: